Abstract
Background: One of the approaches to cancer gene therapy relies on tumor transfection with DNA encoding toxins under the control of tumor-specific promoters.
Methods: Here, we used DNA plasmids encoding very potent anti-ERBB2 targeted toxin, driven by the human telomerase promoter or by the ubiquitous CAG promoter (pTERT-ETA and pCAG-ETA) and linear polyethylenimine to target cancer cells.
Results: We showed that the selectivity of cancer cell killing by the pTERT-ETA plasmid is highly dependent upon the method of preparation of DNA-polyethylenimine complexes. After adjustment of complex preparation protocol, cell lines with high activity of telomerase promoter can be selectively killed by transfection with the pTERT-ETA plasmid. We also showed that cells transfected with pTERT-ETA and pCAG-ETA plasmids do not exert any detectable bystander effect in vitro.
Conclusion: Despite this, three intratumoral injections of a plasmid-polyethylenimine complex resulted in substantial growth retardation of a poorly transfectable D2F2/E2 tumor in mice. There were no significant differences in anti-tumor properties between DNA constructs with telomerase or CAG promoters in vivo.
Keywords: Gene therapy, pseudomonas exotoxin A, PE40, targeted therapy, transfection, polyethylenimine.
Graphical Abstract
[http://dx.doi.org/10.1097/MD.0000000000001301]
[http://dx.doi.org/10.1073/pnas.1008261107]
[http://dx.doi.org/10.1089/hum.2009.083]
[http://dx.doi.org/10.1038/sj.cgt.7700454]
[http://dx.doi.org/10.1016/j.jconrel.2016.05.020]
[http://dx.doi.org/10.1016/0092-8674(78)90099-5]
[http://dx.doi.org/10.1038/sj.cgt.7700115]
[http://dx.doi.org/10.1038/sj.cgt.7700943]
[http://dx.doi.org/10.4161/cbt.7.10.6562]
[http://dx.doi.org/10.1158/1541-7786.MCR-14-0199]
[http://dx.doi.org/10.3389/fmicb.2015.00963]
[http://dx.doi.org/10.1002/stem.1874]
[http://dx.doi.org/10.1126/science.7605428]
[http://dx.doi.org/10.18632/oncotarget.25512]
[http://dx.doi.org/10.1038/msb.2010.99]
[http://dx.doi.org/10.1186/1479-5876-8-134]
[http://dx.doi.org/10.1111/j.1600-065X.2011.01040.x]